SCHEDULE: Nantahala Capital Discloses 9.99% Stake in Quince

Nantahala Capital Management, LLC and its managing members disclosed a 9.99% beneficial ownership stake in Quince Therapeutics, Inc. common stock.

Summary

• Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 4,765,862 shares of Quince Therapeutics, Inc. Common Stock.
• This aggregate amount represents 9.99% of the total outstanding shares of Quince Therapeutics, Inc.
• The reported shares include 2,237,562 shares that can be acquired by the Reporting Persons within sixty days through the exercise of warrants.
• The shares are held by funds and separately managed accounts under Nantahala's control.
• The acquisition and holding of these securities are stated to be in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects, beyond the fact of a significant investment.

Positives

• The filing indicates a significant investment by an institutional investor, potentially signaling confidence in Quince Therapeutics, Inc.

Future Outlook

NA

Management Comments

• The securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects an investment firm's strategic positioning within the biotechnology sector, indicating a significant stake in a publicly traded therapeutic company.

Related Party Transactions

• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala Capital Management, LLC, has the right to receive or direct dividends and proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders gain transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

Quince Therapeutics, Nantahala Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology